Shuangmei Tong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shuangmei Tong has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Jing Ma
Department of Clinical Pharmacy, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200240, China
2 shared publicationsMi Li
Department of Clinical Pharmacy, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200240, China
2 shared publicationsA-Jing Xu
Department of Clinical Pharmacy, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200240, China
1 shared publication- Ajing Xu
Department of Clinical Pharmacy, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, China
1 shared publication - Bin Wang
Department of Pharmacy, Huashan hospital, Fudan University, Shanghai, China
1 shared publication Hong-Yan Zhu
Department of Clinical Pharmacy, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200240, China
1 shared publication
Latest Publications
- Open Access
- 11 February 2026
- Published by Wiley in Clinical and Translational Medicine
- Vol. 16 (2) , e70617
Targeting lysine methyltransferase 2C deficiency: New frontiers in breast cancer therapy and prognosis
Loss‐of‐function mutations in lysine methyltransferase 2 (KMT2C) are frequently observed in breast cancer and are significantly associated with enhanced tumour heterogeneity, aggressive clinical behaviour, and poor prognosis. Although KMT2C has been established as a tumour suppressor, the precise molecular mechanisms by which its deficiency drives metastasis and therapy resistance remain incompletely understood. This review comprehensively examines the multifaceted roles of KMT2C in breast cancer pathogenesis, with a particular emphasis on its interplay with critical oncogenic signalling networks and functional axes, including the IFNγ‐EMT/MET axis, the MAPK/ERK and RAS/PI3K/AKT/mTOR pathways, and the KDM6A–MMP3 regulatory circuit. Furthermore, we discuss emerging therapeutic strategies for KMT2C‐deficient breast cancers, such as epigenetic modulators (EZH2 inhibitors, KDM6A inhibitors, and BET inhibitors), DNA damage response (DDR)‐targeting agents, and pathway‐specific inhibitors. These insights not only elucidate the complex biological functions of KMT2C in breast cancer but also provide a rationale for developing precision therapies tailored to KMT2C‐mutant tumours.
- 11 February 2026
- Published by Wiley in Clinical and Translational Medicine
- Vol. 16 (2) , e70617
Open AccessTargeting lysine methyltransferase 2C deficiency: New frontiers in breast cancer therapy and prognosis
Loss‐of‐function mutations in lysine methyltransferase 2 (KMT2C) are frequently observed in breast cancer and are significantly associated with enhanced tumour heterogeneity, aggressive clinical behaviour, and poor prognosis. Although KMT2C has been established as a tumour suppressor, the precise molecular mechanisms by which its deficiency drives metastasis and therapy resistance remain incompletely understood. This review comprehensively examines the multifaceted roles of KMT2C in breast cancer pathogenesis, with a particular emphasis on its interplay with critical oncogenic signalling networks and functional axes, including the IFNγ‐EMT/MET axis, the MAPK/ERK and RAS/PI3K/AKT/mTOR pathways, and the KDM6A–MMP3 regulatory circuit. Furthermore, we discuss emerging therapeutic strategies for KMT2C‐deficient breast cancers, such as epigenetic modulators (EZH2 inhibitors, KDM6A inhibitors, and BET inhibitors), DNA damage response (DDR)‐targeting agents, and pathway‐specific inhibitors. These insights not only elucidate the complex biological functions of KMT2C in breast cancer but also provide a rationale for developing precision therapies tailored to KMT2C‐mutant tumours.
- 12 February 2025
- Published by Elsevier in Phytomedicine
- Vol. 139, 156473
Baicalin alleviates lipid metabolism disorders in diabetic kidney disease via targeting FKBP51
- 12 February 2025
- Published by Elsevier in Phytomedicine
- Vol. 139, 156473
Baicalin alleviates lipid metabolism disorders in diabetic kidney disease via targeting FKBP51
- Top Cited PapersOpen Access
- 24 January 2025
- Published by Elsevier in Phytomedicine
- Vol. 138, 156406
Targeting the NF-κB p65-MMP28 axis: Wogonoside as a novel therapeutic agent for attenuating podocyte injury in diabetic nephropathy
- 24 January 2025
- Published by Elsevier in Phytomedicine
- Vol. 138, 156406
Top Cited PapersOpen AccessTargeting the NF-κB p65-MMP28 axis: Wogonoside as a novel therapeutic agent for attenuating podocyte injury in diabetic nephropathy
- Open Access
- 9 July 2024
- Published by Springer Nature in Cell Death Discovery
- Vol. 10 (1) , 1-17
IDH1-mutant metabolite D-2-hydroxyglutarate inhibits proliferation and sensitizes glioma to temozolomide via down-regulating ITGB4/PI3K/AKT
The heterogeneous molecular subtypes of gliomas demonstrate varied responses to chemotherapy and distinct prognostic outcomes. Gliomas with Isocitrate dehydrogenase 1 (IDH1) mutation are associated with better outcomes and are more responsive to temozolomide (TMZ) compared to those without IDH1 mutation. IDH1-mutant gliomas elevate D-2-hydroxyglutarate (D-2HG) levels, with potential dual effects on tumor progression. Limited research has explored the potential anti-glioma effects of D-2HG in combination with TMZ. Clinical data from over 2500 glioma patients in our study confirms that those with IDH1 mutations exhibit enhanced responsiveness to TMZ chemotherapy and a significantly better prognosis compared to IDH1 wild-type patients. In subsequent cellular experiments, we found that the IDH1-mutant metabolite D-2HG suppresses Integrin subunit beta 4 (ITGB4) expression, and down-regulate the phosphorylation levels of PI3K and AKT, ultimately inhibiting cell proliferation while promoting apoptosis, thereby improving glioma prognosis. Additionally, we have demonstrated the synergistic effect of D-2HG and TMZ in anti-glioma therapy involved inhibiting the proliferation of glioma cells and promoting apoptosis. Finally, by integrating data from the CGGA and TCGA databases, it was validated that ITGB4 expression was lower in IDH1-mutant gliomas, and patients with lower ITGB4 expression were associated with better prognosis. These findings indicate that ITGB4 may be a promising therapeutic target for gliomas and D-2HG inhibits proliferation and sensitizes glioma to temozolomide via down-regulating ITGB4/PI3K/AKT. These findings drive theoretical innovation and research progress in glioma therapy.
- 9 July 2024
- Published by Springer Nature in Cell Death Discovery
- Vol. 10 (1) , 1-17
Open AccessIDH1-mutant metabolite D-2-hydroxyglutarate inhibits proliferation and sensitizes glioma to temozolomide via down-regulating ITGB4/PI3K/AKT
The heterogeneous molecular subtypes of gliomas demonstrate varied responses to chemotherapy and distinct prognostic outcomes. Gliomas with Isocitrate dehydrogenase 1 (IDH1) mutation are associated with better outcomes and are more responsive to temozolomide (TMZ) compared to those without IDH1 mutation. IDH1-mutant gliomas elevate D-2-hydroxyglutarate (D-2HG) levels, with potential dual effects on tumor progression. Limited research has explored the potential anti-glioma effects of D-2HG in combination with TMZ. Clinical data from over 2500 glioma patients in our study confirms that those with IDH1 mutations exhibit enhanced responsiveness to TMZ chemotherapy and a significantly better prognosis compared to IDH1 wild-type patients. In subsequent cellular experiments, we found that the IDH1-mutant metabolite D-2HG suppresses Integrin subunit beta 4 (ITGB4) expression, and down-regulate the phosphorylation levels of PI3K and AKT, ultimately inhibiting cell proliferation while promoting apoptosis, thereby improving glioma prognosis. Additionally, we have demonstrated the synergistic effect of D-2HG and TMZ in anti-glioma therapy involved inhibiting the proliferation of glioma cells and promoting apoptosis. Finally, by integrating data from the CGGA and TCGA databases, it was validated that ITGB4 expression was lower in IDH1-mutant gliomas, and patients with lower ITGB4 expression were associated with better prognosis. These findings indicate that ITGB4 may be a promising therapeutic target for gliomas and D-2HG inhibits proliferation and sensitizes glioma to temozolomide via down-regulating ITGB4/PI3K/AKT. These findings drive theoretical innovation and research progress in glioma therapy.